RE: Its all in the RNS20 Jan 2021 08:48
The last paragraph of the RNS is quite revealing for those that notice.
No longer -- could be ,,maybe ,, could help, maybe affective, shown to help, etc.
Now its saying.
{The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.}
Main news due on this soon but looking very very positive. If they are speeding things up, we can get this to the market early and cheaply due to covid-19 need ? win win